SCM
IMNM icon

Silverarc Capital Management’s Immunome IMNM Stock Holding History

Silverarc Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.7M Buy
2,017,009
+166,731
+9% +$3.57M 4.44% 5
2026
Q1 		$40.5M Buy
1,850,278
+724,068
+64% +$16.1M 4.13% 6
2025
Q4 		$24.2M Buy
+1,126,210
New +$19.8M 3.36% 10
2024
Q2 		– Sell
-7,489
Closed -$185K – 78
2024
Q1 		$185K Buy
+7,489
New +$152K 0.05% 74

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Silverarc Capital Management's IMNM Position: Q2 2026 in Review

Silverarc Capital Management increased its Immunome (IMNM) stake by 9% in Q2 2026, buying an estimated $3.57M and bringing the position to 2,017,009 shares worth $42.7M. The position accounts for 4.44% of the portfolio, ranked #5.

Silverarc Capital Management first reported a position in IMNM in Q1 2024 and has held it in 4 quarters since. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Silverarc Capital Management held 2,017,009 shares of Immunome worth $42.7M as of Q2 2026.
  • Silverarc Capital Management bought 166,731 Immunome shares in Q2 2026, an estimated $3.57M.
  • Immunome made up 4.44% of Silverarc Capital Management's portfolio in Q2 2026, its #5 holding.
  • Silverarc Capital Management first reported a position in Immunome in Q1 2024 and has held it in 4 quarters since.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.